A Phase 0/I trial on pancreatic cancer with FGFR1 amplification demonstrated that combined treatment with Nintedanib (200 mg/bid) and Letrozole resulted in a 55% average increase in plasma FGF23 levels, indicating effective FGFR1 inhibition [36]. Here, FGFR1 is linked to familial pancreatic carcinoma.